|
1
|
McKeown F: Oat-cell carcinoma of the
oesophagus. J Pathol Bacteriol. 64:889–891. 1952. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner B, Tang LH, Klimstra DS and Kelsen
DP: Small-cell carcinomas of the gastrointestinal tract: a review.
J Clin Oncol. 22:2730–2739. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lv J, Liang J, Wang J, et al: Primary
small cell carcinoma of the esophagus. J Thorac Oncol. 3:1460–1465.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klöppel G, Rindi G, Perren A, Komminoth P
and Klimstra DS: The ENETS and AJCC/UICC TNM classifications of the
neuroendocrine tumors of the gastrointestinal tract and the
pancreas: a statement. Virchows Arch. 456:595–597. 2010.PubMed/NCBI
|
|
5
|
Williams E and Sandler M: The
classification of carcinoid tumours. Lancet. 7275:238–239. 1963.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Solcia E, Klöppel G and Sobin LH:
Histological Typing of Endocrine Tumours. World Health Organization
- International Histological Classification of Tumours. 2nd
edition. Springer; Berlin, Germany: 2000, View Article : Google Scholar
|
|
7
|
Klöppel G: Classification and pathology of
gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat
Cancer. 18(Suppl 1): S1–S16. 2011.
|
|
8
|
Rice TW: Staging of esophageal cancer: TNM
and beyond. Esophagus. 7:189–195. 2010. View Article : Google Scholar
|
|
9
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th edition.
Wiley-Blackwell; Oxford, UK: 2009
|
|
10
|
Stahel RA, Ginsberg R, Havemann K, et al:
Staging and prognostic factors in small cell lung cancer; a
consensus report. Lung Cancer. 5:119–126. 1989. View Article : Google Scholar
|
|
11
|
Rindi G and Wiedenmann B: Neuroendocrine
neoplasms of the gut and pancreas: new insights. Nat Rev
Endocrinol. 8:54–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Howard S, O’Regan K, Jagannathan J,
Krajewski K, Giardino A and Ramaiya N: Extrapulmonary small cell
carcinoma: a pictorial review. AJR Am J Roentgenol. 197:W392–W398.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Frazier SR, Kaplan PA and Loy TS: The
pathology of extrapulmonary small cell carcinoma. Semin Oncol.
34:30–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li AF, Li AC, Hsu CY, Li WY, Hsu HS and
Chen JY: Small cell carcinomas in gastrointestinal tract:
immunohistochemical and clinicopathological features. J Clin
Pathol. 63:620–625. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines): Small Cell Lung Cancer. 2012.http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
Accessed October 2, 2012.
|
|
16
|
Kanzaki M, Muto Y, Yoshinouchi S, Maeda M,
Miyoshi S and Teshima S: A case of esophageal small cell carcinoma
with syndrome of inappropriate antidiuretic hormone secretion. Gan
To Kagaku Ryoho. 37:1941–1944. 2010.PubMed/NCBI
|
|
17
|
Mizuiri H, Hihara J and Okada M:
CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell
carcinoma. Gan To Kagaku Ryoho. 36:831–834. 2009.
|
|
18
|
Nakajima S, Hidaka H, Umekita Y, Uchiyama
S, Kataoka H and Chijiiwa K: A 4-year survivor of small cell
carcinoma of the esophagus with liver metastases managed by
multidisciplinary treatment. J Jpn Surg Assoc. 64:1605–1610.
2009.
|
|
19
|
Matsuoka M, Boku N, Yoshino T, Hironaka S,
Onozawa Y, Fukutomi A, Zenda S, Yamazaki K, Yasui H, Hasuike N,
Inui T, Yamaguchi Y, Ono H and Kamata M: Small cell carcinoma of
the esophagus responding to fourth-line chemotherapy with weekly
paclitaxel. Int J Clin Oncol. 10:429–432. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsujie M, Shibata N, Nomura T, Tanaka T,
Morimoto T, Fujita S, Kitani K, Nakahira S, Okuda H and Takeda M: A
patient with stage IVb small cell carcinoma of the esophagus who
survived 23 months after systemic cancer chemotherapy. Gan To
Kagaku Ryoho. 30:271–275. 2003.PubMed/NCBI
|
|
21
|
Koide N, Hiraguri M, Kishimoto K, Nakamura
T, Adachi W, Miyabayashi H, Terai N and Amano J: Small cell
carcinoma of the esophagus with reference to alternating multiagent
chemotherapy: report of two cases. Surg Today. 33:294–298. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yun JP, Zhang MF, Hou JH, et al: Primary
small cell carcinoma of the esophagus: clinicopathological and
immunohistochemical features of 21 cases. BMC Cancer. 7:382007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shia J, Tang LH, Weiser MR, et al: Is
nonsmall cell type high-grade neuroendocrine carcinoma of the
tubular gastrointestinal tract a distinct disease entity? Am J Surg
Pathol. 32:719–731. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gregory DL, Brennan SM, Stillie A, et al:
Impact of 18F-fluorodeoxyglucose positron emission tomography in
the staging and treatment response assessment of extra-pulmonary
small-cell cancer. J Med Imaging Radiat Oncol. 54:100–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vyleta M and Coldwell D: Radioembolization
in the treatment of neuroendocrine tumor metastases to the liver.
Int J Hepatol. 2011:7853152011.PubMed/NCBI
|
|
26
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines): Neuroendocrine Tumors. 2011.http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.
Accessed October 2, 2012.
|
|
27
|
Raymond E, Dahan L, Raoul JL, et al:
Sunitinib malate for the treatment of pancreatic neuroendocrine
tumors. N Eng J Med. 364:501–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao JC, Shah MH, Ito T, et al; RAD001 in
Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study
Group: Everolimus for advanced pancreatic neuroendocrine tumors. N
Eng J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Noda K, Nishiwaki Y, Kawahara M, et al;
Japan Clinical Oncology Group: Irinotecan plus cisplatin compared
with etoposide plus cisplatin for extensive small-cell lung cancer.
N Eng J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanna N, Bunn PA Jr, Langer C, et al:
Randomized phase III trial comparing irinotecan/cisplatin with
etoposide/cisplatin in patients with previously untreated
extensive-stage disease small-cell lung cancer. J Clin Oncol.
24:2038–2043. 2006. View Article : Google Scholar
|
|
31
|
Lara PN Jr, Natale R, Crowley J, et al:
Phase III trial of irinotecan/cisplatin compared with
etoposide/cisplatin in extensive-stage small-cell lung cancer:
clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol.
27:2530–2535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ettinger DS, Jotte R, Lorigan P, et al:
Phase II study of amrubicin as second-line therapy in patients with
platinum-refractory small-cell lung cancer. J Clin Oncol.
28:2598–2603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Onoda S, Masuda N, Seto T, et al; Thoracic
Oncology Research Group Study 0301: Phase II trial of amrubicin for
treatment of refractory or relapsed small-cell lung cancer:
Thoracic Oncology Research Group Study 0301. J Clin Oncol.
24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Asayama M, Fuse N, Yoshino T, et al:
Amrubicin for the treatment of neuroendocrine carcinoma of the
gastrointestinal tract: a retrospective analysis of five cases.
Cancer Chemother Pharmacol. 68:1325–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim YH and Mishima M: Second-line
chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev.
37:143–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kuo CH, Hsieh CC, Chan ML, Li AF, Huang
MH, Hsu WH and Hsu HS: Small cell carcinoma of the esophagus: a
report of 16 cases from a single institution and literature review.
Ann Thorac Surg. 91:373–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
